You are currently viewing Sunshine Biopharma Discusses The Progress of Its COVID-19 and Anticancer  Compounds with The Stock Day Podcast

Sunshine Biopharma Discusses The Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast

For Immediate Release February 17, 2021

Phoenix, February 17th, 2021 (Newsfile Corp.) — The Stock Day Podcast welcomed  Sunshine Biopharma (SBFM)(“the Company”), a company engaged in the development of Adva-27a, a unique anticancer compound, as well as the development of a treatment for COVID-19. CEO of the Company, Dr. Steve Slilaty, joined Stock Day host Everett  Jolly.  

Jolly began the interview by commenting on the Company’s significant increase in stock  price over the past several months. “I think the market recognizes the significant  progress that we’ve been making, and we’re very excited about the science we’ve been  doing,” shared Dr. Slilaty.  

“Could you give us an update on the licensing agreement with the University of  Georgia?”, asked Jolly. “Initially, we teamed up with the University of Georgia because  they had worldwide renowned expertise in coronavirus protease inhibitors, and this is  what our coronavirus treatment is centered around,” explained Dr. Slilaty. “The  University of Georgia had two technologies which were already patented by them and  we agreed that they would license them to us on an exclusive basis. In return, we would  offer co-development of their compounds in parallel with our own.”  

Jolly then asked about the progress of the Company’s COVID-19 treatment. “We are  now at the stage where we have initiated mice studies on our SBFM-PL4 protease  inhibitor,” said Dr. Slilaty, adding that the Company will also be including the licensed  compounds from the University of Georgia in these studies. Dr. Slilaty then elaborated  on the process of the mice studies, as well as what would occur in the event of a  successful study. “If that were the case, we would file our results with the FDA and  request that the FDA authorizes us to proceed to test our compound on actual COVID 19 patients.” 

The conversation then turned to the Company’s development of Adva-27a. “So, that is  our flagship anticancer compound,” explained Dr. Slilaty. “It is the only drug we’re aware  of anywhere in the world that works on multidrug resistant cancer cells,” he shared.  “We’re really excited about this. We have ordered a new batch of Adva-27a, and we’re  expecting delivery of the new batch any time now,” said Dr. Slilaty, adding that the  Company intends to use the compound in mice studies. 

“What’s next for the COVID-19 research plan?”, asked Jolly. “At the end of the mice  studies, we’re going to file the data of the mice studies with the FDA and request a 

review of our results, as well as authorization to proceed with Phase I clinical trials on  actual COVID-19 patient volunteers,” explained Dr. Slilaty. “What’s interesting with our  drug is the fact that it can be taken orally at home. There is no need for a hospital  setting, as is the case right now with current treatments.” 

To close the interview, Dr. Slilaty thanked listeners and shareholders for their support  and interest as they continue to develop treatments for COVID-19 and cancer. “We  hope that we will make a difference in reducing the number of deaths not only in the  United States, but around the world.” 

To hear Dr. Steve Slilaty’s entire interview, follow the link to the podcast here: covid-19-and-anticancer-compounds-with-the-stock 

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages  listeners to visit the company’s message board at 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine  Biopharma is engaged in the development Adva-27a, a unique anticancer compound.  Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying  Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung  Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for  Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish  General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and  intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current  expectations, forecasts, and assumptions that involve risks as well as uncertainties that  could cause actual outcomes and results to differ materially from those anticipated or 

expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and  future growth for upcoming quarterly and annual periods. These risks and uncertainties  are further defined in filings and reports by the Company with the U.S. Securities and  Exchange Commission (SEC). Actual results and the timing of certain events could  differ materially from those projected in or contemplated by the forward-looking  statements due to a number of factors detailed from time to time in our filings with the  SEC. Among other matters, the Company may not be able to sustain growth or achieve  profitability based upon many factors including but not limited to general stock market  conditions. Reference is hereby made to cautionary statements set forth in the  Company’s most recent SEC filings. We have incurred and will continue to incur  significant expenses in our expansion of our existing as well as new service lines noting  there is no assurance that we will generate enough revenues to offset those costs in  both the near and long term. Additional service offerings may expose us to additional  legal and regulatory costs and unknown exposure(s) based upon the various  geopolitical locations we will be providing services in, the impact of which cannot be  predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected]

About The “Stock Day” Podcast 

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and  Micro-Cap companies. It educates investors while simultaneously working with penny  stock and OTC companies, providing transparency and clarification of under-valued,  under-sold Micro-Cap stocks of the market. Stock Day provides companies with  customized solutions to their news distribution in both national and international media  outlets. The Stock Day Podcast is the number one radio show of its kind in America. 


Stock Day Media 

(602) 821-1102